Literature DB >> 7819713

Elevated endothelin levels in patients with hyperlipoproteinemia.

T Haak1, W März, E Jungmann, S Hausser, R Siekmeier, W Gross, K H Usadel.   

Abstract

We determined lipoproteins, apolipoproteins, and endothelin in 98 patients (58 female and 40 male, age 18-72 years) with hyperlipidemia (plasma cholesterol > 2.5 g/l and/or triglycerides > 2.0 g/l) and in 50 healthy subjects (20 female, 30 male, age 19-68 years). In patients with hyperlipidemia endothelin levels were elevated compared to healthy controls. Patients with plasma cholesterol above 2.5 g/l had higher endothelin and lipoprotein(a) concentrations than patients with plasma cholesterol levels less than 2.5 g/l. A positive correlation was found between the concentrations of endothelin and apolipoprotein B (r = 0.2137; P < 0.013). Smoking patients with lipoprotein (a) above 300 mg/l had higher endothelin levels than both nonsmoking patients with lipoprotein (a) above 300 mg/l and smokers with normal lipoprotein(a). In smokers endothelin correlated positively with Lp(a) (r = 0.709; P < 0.01). No correlation was found between endothelin and triglycerides nor between endothelin and age or sex. The results suggest that the vasoconstrictor endothelin contributes to the increased vasal tone in hyperlipidemia. Because endothelin also has mitogenic properties, it may play a relevant role in the development of premature atherosclerosis in patients with hyperlipidemia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7819713     DOI: 10.1007/bf00227448

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  30 in total

1.  Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group.

Authors:  J D Neaton; D Wentworth
Journal:  Arch Intern Med       Date:  1992-01

Review 2.  Lipoprotein (a). Heterogeneity and biological relevance.

Authors:  A M Scanu; G M Fless
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

3.  Genetics of the quantitative Lp(a) lipoprotein trait. I. Relation of LP(a) glycoprotein phenotypes to Lp(a) lipoprotein concentrations in plasma.

Authors:  G Utermann; H G Kraft; H J Menzel; T Hopferwieser; C Seitz
Journal:  Hum Genet       Date:  1988-01       Impact factor: 4.132

4.  Endothelin is a potent mitogen for rat vascular smooth muscle cells.

Authors:  Y Hirata; Y Takagi; Y Fukuda; F Marumo
Journal:  Atherosclerosis       Date:  1989-08       Impact factor: 5.162

5.  Effects of atherosclerosis and regression on vascular responses to products of activated platelets in primates.

Authors:  J A Lopez; M L Armstrong; A F Brotherton; D J Piegors; D D Heistad
Journal:  Am J Physiol       Date:  1991-04

6.  Determination of lipoprotein(a): evaluation of three methods.

Authors:  W März; R Siekmeier; W Gross; G M Kostner
Journal:  Eur J Clin Chem Clin Biochem       Date:  1993-05

7.  Impaired endothelium-dependent relaxation to aggregating platelets and related vasoactive substances in porcine coronary arteries in hypercholesterolemia and atherosclerosis.

Authors:  H Shimokawa; P M Vanhoutte
Journal:  Circ Res       Date:  1989-05       Impact factor: 17.367

8.  Lipoprotein(a) in ischemic cerebrovascular disease: a new approach to the assessment of risk for stroke.

Authors:  G Jürgens; P Költringer
Journal:  Neurology       Date:  1987-03       Impact factor: 9.910

9.  A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels.

Authors:  M Yanagisawa; H Kurihara; S Kimura; K Goto; T Masaki
Journal:  J Hypertens Suppl       Date:  1988-12

10.  Relationship between lipids and angiographically defined coronary artery disease in Japanese patients.

Authors:  K Kanamori; H Nishijima; S Kojima; N Matsumura; I Sato; R Murakami; M Minami; H Yasuda
Journal:  Am Heart J       Date:  1984-11       Impact factor: 4.749

View more
  5 in total

Review 1.  The therapeutic potential of endothelin receptor antagonists in cardiovascular disease.

Authors:  M Barton; W Kiowski
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

Review 2.  ET-1 as a Sex-Specific Mechanism Impacting Age-Related Changes in Vascular Function.

Authors:  Andrew V Kuczmarski; Laura M Welti; Kerrie L Moreau; Megan M Wenner
Journal:  Front Aging       Date:  2021-08-31

3.  Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis.

Authors:  Eugenia Raichlin; Abhiram Prasad; Verghese Mathew; Bailey Kent; David R Holmes; Geralyn M Pumper; Rebecca E Nelson; Lilach O Lerman; Amir Lerman
Journal:  Hypertension       Date:  2008-08-11       Impact factor: 10.190

4.  Endothelin-1 does not prime polymorphonuclear leukocytes for enhanced production of reactive oxygen metabolites.

Authors:  S Kopprasch; A Gatzweiler; M Kohl; H E Schröder
Journal:  Inflammation       Date:  1995-12       Impact factor: 4.092

5.  Endothelin-1 modulates methacholine-induced cutaneous vasodilatation but not sweating in young human skin.

Authors:  Lyra Halili; Maya Sarah Singh; Naoto Fujii; Lacy M Alexander; Glen P Kenny
Journal:  J Physiol       Date:  2016-03-11       Impact factor: 5.182

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.